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Abstract 
A single copy of klotho allele KL-VS is associated with longevity, better health, increased cognition 
and bigger regional brain volume. However, its longitudinal effects on cognition and brain volumes, 
both global and regional, in late life are unclear. In this study we show [1] KL-VS heterozygotes had 
shorter survival and [2] smaller white matter volumes than non-carriers; [3] had slower cognitive 
decline; and [4] had greater right frontal lobe volumes. The KL-VS heterozygote survival and white 
matter volume disadvantages were unexpected. A possible explanation for these results in the 
context of the literature is a potential interaction between the environment and/or age of the 
participants, leading to a heterozygote disadvantage. The longitudinal cognitive trajectories indicate 
that heterozygotes would have an advantage in very late life. Collectively these results suggest that 
the genotype-survival advantage of the KL-VS allele is age-dependent and possibly mediated through 
differential cognition and brain volume.  
Keywords 
Klotho; cognitive aging; brain atrophy; survival; APOEε4 
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1. Introduction 
To live a long, fruitful and independent life is not a matter of chance. Interplay between genes and 
environment lies at the heart of understanding individual differences in rates of aging. An important 
requirement for a life free from disability is a healthy brain. The aging brain undergoes structural and 
functional changes that correlate with cognitive decline (Staff et al., 2006, Waiter et al., 2008). There 
are marked individual differences in terms of premorbid abilities and the rate of decline (Staff et al., 
2016), which are influenced by genetics (Kenyon, 2010). Identifying genetic factors that influence 
anatomical and functional changes of the aging brain will increase understanding of healthy brain 
aging. Here, we investigate the effects of an established genetic influence on health in late life–
polymorphisms in the klotho gene– on cognitive aging, structural changes in the aging brain and 
survival. If the role of the klotho protein on cognitive aging and possible dementia could be 
established, klotho’s potential function as an anti-aging protein could become a therapeutic target. 
Compounds that mimic the actions of klotho could emulate its effect in the brain and be beneficial in 
demyelinating and neurodegenerative diseases (Abraham et al., 2012, Zeldich et al., 2015).  Klotho’s 
potential influence on aging is one of many. The role of apolipoprotein E-ε4 (APOEε4) has been 
extensively investigated, establishing the significant contributions of apolipoprotein E-ε4 (APOEε4) 
to longevity (Soerensen et al., 2013), cognitive aging (Jochemsen et al., 2012), and brain volumes. 
These associations mandate the analysis of APOEε4 in this context, in order to establish the 
independence of klotho’s effects from those of APOEε4. 
Klotho is a transmembrane protein present in blood and cerebrospinal fluid when cleaved from the 
cell surface. Circulating klotho affects glycoproteins on brain cell surfaces and multiple organs 
throughout the body (Imura et al., 2004). Klotho has multiple roles including renal function and 
growth factor inhibition (Kurosu et al., 2005). These pleiotropic actions may explain how klotho 
influences aging processes (Dubal et al., 2015). In mouse models of aging, a defect of klotho gene 
expression results in multiple aging-like phenotypes including short lifespan, skin atrophy, 
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osteoporosis and atherosclerosis (Kuro-o et al., 1997), whereas klotho over-expression suppresses 
aging and extends lifespan (Kurosu et al., 2005). Moreover, klotho has been shown to causatively 
enhance cognitive function in mice (Dubal et al., 2014). Two variants in humans co-segregate and 
form a haplotype, KL-VS (Yokoyama et al., 2015). The heterozygous polymorphism of KL-VS increases 
secreted forms of klotho, may increase longevity, promotes Fibroblast Growth Factor signaling and 
decreases risk of heart disease (Arking et al., 2002, Arking et al., 2005). In addition to these anti-
aging actions, klotho appears differentially expressed during post-natal neurodevelopment (Clinton 
et al., 2013), is involved in the maturation of long white matter tracts (Chen et al., 2013), and 
promotes brain maturation and synaptic plasticity (Dubal et al., 2015). 
In human studies KL-VS genotype contributes to cognitive differences in early and late-life and to 
regional brain volumes in the frontal cortex (Deary et al., 2005, Dubal et al., 2014, Houlihan et al., 
2009, Yokoyama et al., 2015). Yokoyama et al. 2015 (Yokoyama et al., 2015) suggest one copy of the 
KL allele KL-VS increases cognition and grey matter volume within the right dorsolateral prefrontal 
cortex (rDLPFC) compared to non-carriers, an area critical to learning and memory. In addition, 
carrying two copies appeared to decrease cognition and rDLPFC volume. Dubal et al. 2014 (Dubal et 
al., 2014) showed KL-VS heterozygosity was associated with increased cognition, and suggested that 
klotho could increase ‘cognitive reserve’, slowing aging. Deary et al. 2005 (Deary et al., 2005) 
showed in the Lothian 1921 Birth Cohort that KL-VS homozygosity was associated with lower 
childhood and late-life cognition. However, Deary et al. 2005 did not find an association between KL-
VS homozygosity and cognition in the Aberdeen 1936 Birth Cohort examined here, or KL-VS 
heterozygosity and cognition in either cohort. Similarly, Houlihan et al. (Houlihan et al., 2009) did not 
find a relationship between KL-VS and early or late-life cognition in the Lothian 1936 Birth Cohort, 
but found that KL-VS carriers have lower four choice reaction times. Transgenic mice with 
moderately elevated klotho expression performed better than controls in multiple tests of learning 
and memory (Dubal et al., 2014, Dubal et al., 2015). However, in humans the effects of KL-VS 
genotype on global brain volumes and cognitive performance trajectories within late-life are unclear. 
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Here, we examine the effects of KL-VS genotype on regional and global brain volumes, survival, 
early-life cognition and late-life longitudinal cognitive change. This holistic approach extends what is 
known about the effects of KL-VS in humans in late life. 
Up to two MRI brain exams were collected. Exam 1 was at a mean age of 69, exam 2 at a mean age 
of 73. The rDLPFC was selected for detailed brain volume analysis, as Yokoyama et al. 2015 found 
rDLPFC grey matter volume varied with KL-VS. The hippocampus was also selected a priori for in 
depth brain analysis because of its importance in healthy aging and Alzheimer’s disease (Jack et al., 
1999, West et al., 1994). 
To measure longitudinal change in cognition, we used the Digit Symbol Substitution (DS) Test. DS 
was administered on up to five occasions between ages 63 and 78 and measures information 
processing speed and short term memory. Performance on DS declines with age (Joy et al., 2004). 
Age-related decline in DS performance is largely independent of participants’ duration of education 
and self-reported health status (Salthouse, 1992). Reports of practice effects are varied possibly 
because these are modest and small compared to the prominent age effect (M. Wielgos, Walter R. 
Cunningham, Cynthia, 1999). DS is, therefore, a suitable measure for more complex causal 
longitudinal modeling of age-related cognitive decline. We used a multilevel linear mixed modeling 
approach to longitudinal cognitive performance data to test contributions of KL-VS and APOEε4. 
Measuring longitudinal decline presents analytical challenges such as data clustering and co-
variances between predictors, which may elucidate relationships between the potential predictors 
of decline. A multilevel linear mixed modeling approach allows such phenomena to be considered.  
Here, we examine the longitudinal influence of KL allele KL-VS on cognition, regional and global brain 
volumes and survival separately and in combination.  In the light of actions of KL-VS on survival, 
brain structure and on cognition, we hypothesize that genetic variation in the KL-VS is associated 
with trajectories of brain aging. Specifically, we hypothesize that variation in KL-VS is associated with 
different trajectories of change in information processing speed (DS test), differences in global and 
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regional brain volumes (both cross-sectionally and longitudinally), and ultimately in survival rates. A 
supplementary analysis of APOEε4’s influence determined whether KL-VS’s effects were 
independent from those of APOEε4. 
2. Methods 
2.1. Sample 
All data were provided by the Aberdeen Birth Cohort of 1936; an extended description of the data 
set is given in Whalley et al. 2011(Whalley et al., 2011). Instructions on how to request access to the 
data can be found on the Aberdeen Birth Cohorts website (http://www.abdn.ac.uk/birth-
cohorts/1936/for-researchers/data-access). Following approval of the Local Ethics of Research 
Committee, volunteers gave written informed consent to the study. The whole sample consists of 
508 participants. 
2.2. Genotyping 
KLF352V and APOE genotypes were determined by TaqMan (Applied Biosystems) analysis, 
performed at the Wellcome Trust Clinical Research Facility, Western General Hospital Edinburgh. 
480 participants provided a relevant KL genotyping sample; 478 participants provided a relevant 
APOE genotyping sample. For KL allele KL-VS, F/F indicates non-carriers, F/V heterozygotes and V/V 
homozygotes. For APOEε4, −APOEε4 indicates non-carriers and +APOEε4 carriers. 
2.3. Cognitive testing 
Childhood cognitive data were provided by the Scottish Council for Research in Education (SCRE) 
from data archived from the Scottish Mental Survey of 1947. Almost all children born in 1936 and at 
school in Scotland on the 4th of June 1947 (aged 11 years), sat a group-administered cognitive test 
(The Moray House Test, MHT) (Deary et al., 2004). A trained psychologist administered the Digit 
Symbol Substitution test (DS) on up to five occasions between the ages of 63 and 78, which assessed 
speed of processing and memory. The total number of correct answers was calculated to give the DS 
score. 
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2.4. Survival follow-up 
On the 5
th 
of January 2015, the vital status of 494 participants was established. No vital status data 
were available for 14 members of the Aberdeen Birth Cohort of 1936 who had left the Grampian 
area. 
2.5. Education and occupation 
Assessment of participants’ duration of full-time education in years, their occupation and their 
father’s occupation were recorded at interview on recruitment. Occupational social class (OSC) was 
coded using the UK Office of Population Statistics Classification (Great Britain: Employment 
Department Group and Great Britain: Office of Population Censuses and Surveys, 1990). The 
occupational groups were coded as follows: managerial –1, professional –2, lesser professional –3, 
secretarial –4, skilled manual –5, semi-skilled ii –6, semi-skilled i –7, unskilled ii –8, and unskilled i –9. 
2.6. Brain image acquisition and processing 
2.6.1. Acquisition 
Up to two MRI Brain images were collected for each participant using a 1.5 Tesla GE NVi system. 
Three-dimensional brain images were obtained with a T1 SPGR (T1W) MR sequence. Not all 
participants volunteered and some were ineligible because of contraindications for brain imaging. 
245 were imaged between the ages 67 and 72 of whom 244 provided usable images; one image was 
removed due to excessive movement during acquisition. 156 individuals had a second T1 weighted 
MRI exam performed, between the ages 71 and 73. 
2.6.2. Processing 
The MRI data collected at exam 1 and 2 were processed cross-sectionally and longitudinally, using 
SPM12 version 6225 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12) and FreeSurfer5.3 software 
(http://freesurfer.net), preceding statistical analysis. 
For the cross-sectional processing, SPM12 processed the MRI data prior to voxel-based 
morphometry (VBM), which compares the images voxel by voxel (Ashburner et al., 2014).  
Processing consists of segmentation, running  Diffeomorphic Anatomical Registration through 
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Exponential Lie Algebra (DARTEL) (Ashburner, 2007) to create a custom template, and normalizing to 
Montreal Neurological Institute (MNI) space. The resultant grey matter (GM) and white matter 
(WM) images were smoothed with an 8 mm kernel. GM and WM volume, total brain volume (TBV), 
total intracranial volume (TICV) and their rate of change were calculated for each participant. For the 
longitudinal processing in SPM12 we used Pair wise Longitudinal Registration and DARTEL to 
generate GM and WM divergence maps that are estimates of the rate of volumetric change 
(Ashburner et al., 2014). 
FreeSurfer was used to carry out automatic volumetric segmentation (Destrieux et al., 2010, Fischl, 
2012) to extract the volume of the rDLPFC and hippocampus. A rDLPFC proxy was constructed from 
the inferior, middle and superior frontal gyri in the right half of the brain (John et al., 2006, Raz et al., 
1997). TBV was also extracted. For the second imaging exam, one participant showed an error in the 
FreeSurfer results, and was excluded from subsequent analyses. To extract rDLPFC/hippocampal 
volume rate of change, the images were automatically processed with the longitudinal stream 
(Reuter et al., 2012) in FreeSurfer. 
2.7. Statistical analysis 
2.7.1. MRI brain volumes 
After MRI data processing, statistical analysis was performed. Baseline exams were analyzed cross-
sectionally to examine global and regional brain volume differences between KL-VS heterozygotes 
and non-carriers, and APOEε4 carriers and non-carriers. Longitudinally, baseline and follow up exams 
were analyzed to examine global and regional brain volume changes differences across groups.  KL-
VS homozygotes were disregarded from this analysis because of their small numbers (n1=10/n2=6). 
To examine global brain differences, SPM12’s baseline whole brain measures TBV, GM and WM 
volume, and their rates of change per year, were compared across groups.  When examining cross-
sectional differences, these volumes were divided by total intracranial volume (TICV), resulting in the 
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measures brain fraction (BF: TBV/TICV), grey matter fraction (GM/TICV) and white matter fraction 
(WM/TICV). 
SPM12 VBM was used to examine regional brain volume differences in GM and WM volume and 
rates of change: the generated normalized GM and WM volume maps, and GM and WM divergence 
maps, were compared across KL-VS and APOEε4 groups. Previous work has indicated that 
differences exist in the right frontal lobe, and in particular the rDLPFC. We applied small volume 
correction in order to focus on this location of interest. A rDLPFC mask was applied, consisting of the 
inferior frontal gyrus, the middle frontal gyrus and the superior frontal gyrus in the right half of the 
brain, which was generated with the SPM12 toolbox WFU PickAtlas (Maldjian et al., 2003). Age at 
exam, gender and TBV were added as covariates to correct for their effects. Longitudinally, the 
generated GM and WM divergence maps were compared across groups using VBM. Gender and age 
at first exam were added as covariates. 
FreeSurfer measures of hippocampal and rDLPFC volume were compared across groups employing 
general linear modeling; FreeSurfer measure of TBV was used to correct for brain size. 
Longitudinally, rDLPFC and hippocampus rate of change per year were compared across groups. 
2.7.2. Cognitive modeling 
Cognition at age 11 (MHT) was compared using a one-way analysis of variance to examine 
differences between KL-VS heterozygotes, homozygotes and non-carriers. T-tests examined 
differences between APOEε4 carriers and non-carriers. 
Longitudinal differences in cognition were examined in participants who provided two or more DS 
data points. The raw DS scores were first standardized to a mean of 100 and a standard deviation of 
15. Age at test was measured as time after the 60
th
 birthday. Multilevel modeling examined the 
trajectory of decline.  , represents the test score for participant j on occasion i. KL-VS was coded 
1 for F/V present and 0 for F/V absent.  In Model 1 we assume that current cognitive performance is 
a linear combination of an intercept	(	,), the influence of age	(,), the KL-VS variant(,), 
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gender	(,) and education	(,).  The influence of age, KL and the intercept were modeled as both 
fixed and random. 
, = 	, + ,	+	,(/) + , + , !"# + ,  
2.7.3. Survival analysis 
In order to assess whether there is a relationship between survival time and the potential predicting 
parameters such as cognition and KL-VS genotype, a Cox regression was performed. Here, we 
examined each potentially predicting variable separately and then included variables into a final 
regression model only if it individually predicted survival (p<.05). The final models took two forms: 
one with and one without brain imaging data. 
3. Results 
3.1. Cognitive modeling  
Our sample is described in Table 1 with early-life cognitive scores (MHT) and late-life cognitive 
scores (DS) on entry. We found no cross-sectional differences between KL-VS groups or between 
APOEε4 carriers and non-carriers in terms of childhood ability and DS on entry. Multi-level modeling 
examined differences in longitudinal decline between groups. Figure 1 shows a spaghetti plot for the 
DS test for the whole group. As expected, the test shows a decline with age (=-.87 p<.001); being 
female conveyed an advantage (=4.76 p<.001), as did more education (=1.98 p<.001). The 
presence of F/V has no effect (=.90 ns) on DS (main effect), confirming the cross-sectional analysis. 
F/V significantly co-varies with the slope for age ($,= 5.00 p<.01) indicating an association with the 
trajectory of cognitive decline. When the sample is split into heterozygotes and non-carriers, the 
slopes with age () show a decline with age of -.71 and -.90 respectively. No significant findings 
were observed for homozygotes in a similar analysis, probably attributable to small sample size. 
Replacing klotho with APOEε4 in model 1 showed that presence of APOEε4 had no effect on DS and 
APOEε4 did not co-vary with the slope with age indicating no influence on the rate of decline. 
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Including both KL-VS and APOEε4 in the model produced results not different from the separate KL-
VS and APOEε4 models. 
3.2. Global brain volume analysis 
When first imaged and after adjusting for age and gender KL-VS heterozygotes had smaller WM 
fraction (31.6% vs 30.6%, p=.005). No cross-sectional differences were found when the APOEε4 
groups were compared.  Longitudinally, after adjusting for age and gender, APOEε4 carriers lost 
more TBV and GM than non-carriers (TBV: -10.3 vs -7.5 mm
3
 x10
3
, p=.0031; GM: -7.5 vs -5.3 mm
3
 
x10
3
, p=.011. No longitudinal differences were found when KL-VS heterozygotes and non-carriers 
were compared.  A combined analysis of KL-VS and APOEε4 showed that KL-VS’s association with 
WM is independent of APOEε4 (p=.004), and that APOEε4’s associations with TBV and GM rate of 
change are independent of KL-VS (p=.003 and p=.010 respectively).  Table 2 shows GM, WM and 
TBV, rDLPFC and hippocampal mean volumes per group, and their rates of change. 
3.3. Regional brain volume analysis: rDLPFC and hippocampus 
When first imaged and after adjusting for age and gender, APOEε4 non-carriers had significantly 
more hippocampal volume as percentage of TBV than carriers (.77% vs .75%, p=.026). A combined 
analysis of KL-VS and APOEε4 showed that the associations were independent of KL-VS status: 
APOEε4 remained significant for exam 1 hippocampal volume as percentage of TBV (p=.032). No 
cross-sectional or longitudinal differences were found between KL-VS heterozygotes and non-
carriers.  No longitudinal differences were found betweenAPOEε4 carriers and non-carriers. 
3.4. Regional brain volume analysis: Voxel-based morphometry (VBM) 
Using the images acquired at exam 1 and examining F/V>F/F, at uncorrected p<.001 a GM region 
was found shown (Figure 2a) in the right inferior frontal gyrus. Correcting for multiple comparisons 
using a Family Wise Error (FWE) approach, with pFWE<.05, no significant voxels were identified. 
Applying small volume correction (rDLPFC) a significant corrected area was identified (pFWE<.05) at 
the location indicated in Figure 2.No significant locations were observed for the reverse contrast 
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F/V<F/F.  No significant WM locations (pFWE<.05) were observed.  Longitudinal VBM found no 
significant differences between KL-VS heterozygotes and non-carriers in GM or WM divergence 
maps. 
The APOEε4 VBM analysis found no significant GM or WM differences for exam 1. Longitudinally, 
carriers showed smaller increases and larger decreases in regional brain volume than non-carriers 
(Figure 2b shows the most significant region). Differences in GM with an extent>100mm
3
 were found 
in the right inferior temporal gyrus, and in the middle temporal gyrus. Differences in WM with an 
extent>100mm
3
 were found in the right temporal lobe and in the left fusiform gyrus.  A combined 
analysis of KL-VS and APOEε4 showed that KL-VS heterozygotes have a larger rDLPFC, independent 
of APOEε4, and APOEε4 carriers have a larger decrease in GM and WM, independent of KL-VS. 
3.5. Survival analysis 
The Kaplan-Meier survival curves Figure3a show that KL-VS heterozygotes (F/V) have a shorter 
survival than non-carriers (-VF/F). We have previously shown that brain fraction is a significant 
predictor of survival. Figure 3b shows the KL-VS groups split by brain fraction above and below the 
mean (.754). The figure indicates that greater brain fraction is associated with longer survival.  
Cox regressions separately examined the effect of the non-imaging parameters KL-VS (comparing 
heterozygotes with non-carriers), APOEε4, gender, DS test score at occasion 1, MHT score, years of 
education, and early and late-life OSC on survival. Gender, KL-VS, DS score, MHT score and early-life 
OSC were predictors of survival (p<.05): KL-VS heterozygotes survived shorter than non-carriers 
(hazard ratio or HR: 1.64, p=.014); a higher DS and MHT score were associated with survival (DS HR: 
.97, p<.001; MHT HR: .98, p=.021); a lower early-life OSC was associated with shorter survival (HR: 
1.12, p=.011); males had shorter survival than women (HR: 1.50, p=.027).  The effects of APOEε4, 
years of education and late-life OSC on survival were non-significant. 
We added the significant predictors of survival into one Cox regression, but removed APOEε4, years 
of education and late-life OSC because they were previously non-significant. We found that KL-VS 
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genotype, late-life cognition and childhood socioeconomic circumstance are significant predictors of 
survival.  We repeated the Cox regression analysis using only those who had been imaged, and 
introduced BF as an additional covariate (KL-VS genotype, late life cognition and childhood 
socioeconomic circumstance remained significant predictors of survival in the imaged subset). Early 
life cognition and BF are now significant predictors of survival. Table 2 shows the hazard ratios for 
the two models. 
4. Discussion 
We present a comprehensive analysis of associations between klotho, APOEε4, cognition, brain size 
and survival in a well characterized cohort of elderly people in the North East of Scotland. Previous 
studies have investigated the effects of KL-VS genotype on cognition, local brain volume and 
survival. However, the role of KL-VS on global brain volume and rate of cognitive decline had not 
been explored. Our results show that the klotho allele KL-VS influences the rate of cognitive decline 
and global brain volumes, particularly in the white matter. 
Limitations of the study include the higher likelihood that individuals in better health return for 
follow-up cognitive tests and MRI scans. Furthermore, our sample size was relatively small. Locality-
specific effects attributable to the homogeneity of the sample cannot be excluded. There may be a 
Scotland or even Aberdeen specific circumstance or interaction with an environmental factor that 
influenced our results. However, examining between-cohort differences could improve 
understanding of klotho’s effect on aging. 
The absence of an APOEε4 association with cognition is inconsistent with some published findings.  
This may be in part due to the cohort only recruiting at baseline unimpaired individuals and our 
impression that declining individuals were less likely to return for repeat evaluation.  In addition, 
Small et al. 1998 have found that APOEε4 status may not influence cognitive performance in adults 
without dementia, including processing speed (Small et al., 1998). 
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Our cross-sectional cognition results support Deary et al.’s findings in our cohort (Deary et al., 2005), 
which found no difference between KL-VS heterozygotes and non-carriers.  However, these data do 
not support other studies that indicate heterozygotes have higher cognition than non-carriers (Dubal 
et al., 2014, Yokoyama et al., 2015).  Sources of this discrepancy are unclear. Studies that found 
differences were conducted in older individuals who received more education and who are from 
higher socioeconomic backgrounds. Longitudinally, KL-VS heterozygotes have a slower cognitive 
decline than non-carriers. This indicates that in an older sample heterozygotes would have higher 
cognition. This supports a heterozygous advantage for cohorts that examined older participants 
and/or participants within a larger age range (Dubal et al., 2014, Yokoyama et al., 2015). In addition, 
these differences in decline are independent of APOEε4 status. There may also be a 
klotho/socioeconomic interaction. Prather et al. 2015 (Prather et al., 2015) suggested that klotho 
protein concentrations are sensitive to psychosocial stressors which are associated with 
socioeconomic position (Cohen et al., 2006). In addition, the advantage of KL-VS heterozygosity may 
only be seen in very late-life and non-carriers may have advantages at different times in the life 
course. These two explanations are not mutually exclusive and previous human studies may have 
sampled from populations where the non-carrier advantage was less important given the 
environment and the age range of the study. Similarly, the controlled environment of the animal 
studies may not have exposed the sample to an environment where the non-carrier advantage is 
realized. 
Regional imaging analysis, when using no assumptions about the potential location of differences 
(i.e. whole brain analysis) found no differences between KL-VS groups. However, when guided by 
previous work in the area (Yokoyama et al. 2015) we found a region in the rDLPFC where KL-VS 
heterozygotes had more grey matter than non-carriers. This difference was independent of APOEε4 
status. Although this generally agrees with the earlier study (Yokoyama et al., 2015), our region is 
more posterior than identified previously. This might be because of methodological differences 
between the two analyses: first, as discussed above, the samples are probably different in terms of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Klotho, APOEε4, cognitive ability, brain size, atrophy and survival 
    
15 
 
recruitment; and second the image analysis used different templates which will result in differences 
in the reported coordinates.  
The global brain volume analysis showed that KL-VS heterozygotes had smaller white matter volume 
relative to head size at the first MRI exam. This finding was independent of APOEε4 status.  Greater 
brain volumes are associated with longevity, with individuals with more white matter surviving 
longer (Staff et al., 2010, Van Elderen et al., 2016). Longitudinally, there were no differences in brain 
volume changes, indicating that KL-VS is not associated with rate of atrophy.  
The survival analysis found that KL-VS heterozygotes have a survival disadvantage compared to non-
carriers, which was unexpected. As anticipated from our earlier work in an older sample (Staff et al. 
2010), a greater brain fraction is associated with longer survival (Staff et al., 2010).The effect of KL-
VS on survival remained after adjusting for cognition. This suggests that klotho influences survival 
not (only) through a possible effect on cognition, but also through another mechanism, perhaps 
influencing differential brain atrophy or differential development. This is supported by our finding 
that KL-VS is no longer significant when brain fraction is included in the Cox regression model. 
We have found that KL-VS heterozygosity is associated with both positive and negative effects in the 
Aberdeen Birth Cohort of 1936. KL-VS heterozygotes showed increased rDLPFC volume and a slower 
rate of cognitive decline, but also smaller white matter volumes and decreased rates of survival. 
These results paint a broad picture of the effects of KL-VS in late life and contradict a purely positive 
effect of KL-VS heterozygosity. Projecting forward, the longitudinal cognition result suggests that in 
an older cohort, heterozygotes would have higher cognition than non-carriers, and possibly 
subsequent higher survival. This would be consistent with previous work that found a survival 
advantage for heterozygotes in older groups than the one studied here (Arking et al., 2002, Arking et 
al., 2005), and supports work that suggested that KL-VS's effect on cognition and survival is age-
dependent (Invidia et al., 2010, Mengel-From et al., 2016). 
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5. Conclusion 
Our study demonstrates that KL-VS heterozygosity is associated with slower cognitive decline in 
old age. This may in part explain discrepancies between our findings and other studies that 
examined cross-sectional cognitive estimates. The regional volumetric results, which show a 
difference in the rDLPFC, are consistent with what was previously shown (Yokoyama et al., 2015). 
The global brain volume results demonstrate a relationship between KL-VS and white matter volume 
in late life.  The survival results do not support the hypothesis that KL-VS heterozygotes possess a 
survival advantage, as heterozygotes died earlier. Collectively these results are independent of 
APOEε4 status suggesting that their mechanisms are separate. Taken together, we show a possible 
environmental influence on the action of KL-VS and that action may represent a gene-by-age effect 
and differ across the life course. 
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Figure Legends 
Figure 1: Spaghetti plot for the Digit Symbol test for the whole group. The red lines indicate the non-
carriers and the black lines the heterozygotes. The two bold lines represent the respective trend lines 
for each group. 
Figure 2: Surface renders of grey matter volume differences. Figure 2a shows the most significant 
grey matter region when comparing KL-VS heterozygotes with non-carriers in a whole brain analysis, 
at uncorrected p<.001 (MNI coordinates: 50, 6, 39; extent: 1802mm
3
). After small volume correction 
(rDLPFC) a significant corrected area was identified (pFWE<.05) at the same location (extent: 
118mm
3
). The arrow roughly indicates the location of the rDLPFC area found by Yokoyama et al. 
2015 (MNI coordinates discovery cohort Yokoyama et al.: 39, 26, 36). Figure 2b shows the most 
significant region for which APOEε4 non-carriers had either a larger positive change or a smaller 
negative change in brain volume than carriers, at corrected p<.05. bspmview, an SPM12 toolbox, 
generated the renders. See Supplementary Table 2 for full results of the VBM analyses (groups 
compared, significance level, and peak location in MNI coordinates, cluster size and probabilities). 
Figure 3: Kaplan-Meier survival curves split by: KL-VS heterozygotes and non-carriers (3a), and both 
KL-VS genotype and brain fraction (3b). The plus signs indicate ages of participants alive at the latest 
census date (6th of January 2015). MRI exams were performed when participants were between ages 
68 and 72 years. Genotyping was performed when the participants were 64. 
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Tables 
 
 Whole 
sample (SE) 
F/F 
(N=331) 
F/V 
(N=134) 
V/V 
(N=15) 
−APOEε4 
(N=352) 
+APOEε4 
(N=126) 
Sex-Number Male (N=508) 246, 48.4% 154, 46.5% 72, 53.7% 10, 66.7% 177, 50.3% 59, 46.8% 
OSCadult (N=472) 4.72 (.10) 4.73 (.12) 4.72 (.20) 4.33 (.41) 4.75 (.12) 4.63 (.19) 
OSCchildhood (N=473) 6.21 (.11) 6.15 (.14) 6.25 (.20) 7.13 (.49) 6.15 (.13) 6.39 (.22) 
Education years (N=477) 11.16 (.10) 11.20 (.12) 11.03 (.19) 11.47 (.68) 11.24 (.12) 10.97 (.16) 
Moray House test (N=506) 41.92 (.60) 42.76 (.74) 41.32 (1.16) 44.87 (3.19) 41.78 (.75) 42.40 (1.08) 
DS occasion 1 (N=478) 43.15 (.52) 43.59 (.63) 42.32 (1.06) 44.60 (2.21) 43.18 (.62) 43.56 (1.09) 
Table 1: Demographic and cognitive description of the sample (N=508). Mean values are given. The values 
inside the brackets indicate the standard error (SE). F/F: KL-VS non-carriers, F/V: KL-VS heterozygotes, V/V: KL-
VS homozygotes, −APOEε4: APOEε4 non-carriers, +APOEε4: APOEε4 carriers, OSC: occupational social class. No 
significant differences were found (p<.05). See Supplementary Table 1 for mean DS cognitive scores at 
occasions 1 to 5. 
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 Imaged 
(SE) 
F/F F/V V/V −APOEε4 +APOEε4 
Exam 1 N=244 N=164 N=64 N=10 N=169 N=66 
Sex-Number Male 127, 52.0% 82, 50.0% 36, 56.3% 7, 70.0% 90, 53.3% 35, 53.0% 
Age at MRI years 68.69 (.04) 68.68 (.05) 68.72 (.08) 68.49 (.22) 68.68 (.05) 68.67 (.10) 
TBV mm3 x103 1063.6 (6.8) 1068.7 (8.1) 1048.9 
(14.3) 
1103.6 
(24.8) 
1065.5 (8.0) 1076.5 (12.8) 
TICV mm3 x103 1412.2 (9.0) 1413.0 (10.8) 1408.0 
(18.2) 
1463.4 
(41.3) 
1413.6 (10.6) 1429.5 (17.7) 
rDLPFC mm3 x103 27.63 (.21) 27.68 (.24) 27.36 (.44) 29.53 (.56) 27.70 (.25) 27.82 (.37) 
Hippocampus mm3 
x103 
7.84 (.06) 7.85 (.07) 7.79 (.12) 8.27 (.27) 7.90† (.07) 7.75 (.11) 
Brain Fraction .754 (.002) .757 (.003) .746 (.006) .756 (.010) .755 (.003) .754 (.004) 
GM Fraction .441 (.002) .441 (.002) .440 (.003) .441 (.009) .441 (.002) .441 (.003) 
WM Fraction .313 (.001) .316* (.002) .306 (.004) .315 (.006) .314 (.002) .313 (.003) 
       
Longitudinal N=156/155 N=112/111 N=36 N=6 N=110/109 N=40 
ΔrDLPFC mm3 
x103/year 
-.25 (.02) -.25 (.03) -.27 (.04} -.17 (.07) -.24 (.02) -.30 (.04) 
ΔHippocampus 
mm3x103/year 
-.079 (.007) -.083 (.009) .072 (.011) .031 (.012) -.070 (.006) -0.103 (.021) 
ΔTBV mm3 x103/year -8.18 (.38) -7.96 (.45) -8.55 (.80) -9.08 (1.80) -7.50† (.38) -10.30 (.91) 
ΔGM mm3 x103/year -5.82 (.34) -5.73 (.41) -5.79 (.68) -6.70 (1.73) -5.27† (.35) -7.48 (.87) 
ΔWM mm3 x103/year -2.36 (.19) -2.23 (.22) -2.28 (.41) -2.39 (.19) -2.23 (.22) -2.82 (.37) 
Table 2: Volumetric description of the sample (N=244). Mean values are given. The values inside the brackets 
indicate the standard error (SE). F/F: KL-VS non-carriers, F/V: KL-VS heterozygotes, V/V: KL-VS homozygotes, 
−APOEε4: APOEε4 non-carriers, +APOEε4: APOEε4 carriers, TBV: total brain volume, TICV: total intracranial 
volume, rDLPFC: right dorsolateral prefrontal cortex, brain/GM/WM fraction: TBV/grey matter/white matter 
divided by TICV, Δ denotes the difference between exam 1 and exam 2. The asterisk (*) indicates a significant 
difference (corrected for gender, age) between KL-VS heterozygotes and non-carriers. The dagger (†) indicates 
a significant difference (corrected for gender, age) between APOEε4 carriers and non-carriers (p<.05). 
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covariates  N Sex KL-VS MHT DS OSCchildhood BF 
Non-Imaging 428 
1.20 
(.80, 1.81) 
1.57* 
(1.04, 2.36) 
1.00 
(.98, 1.02) 
.97* 
(.95, .99) 
1.10* 
(1.00, 1.21) 
 
Imaging and Non-
Imaging 
221 
.77 
(.40, 1.46) 
1.32 
(.67, 2.58) 
.96* 
(.93, .99) 
.98  
(.95, 1.01) 
1.13 
(.99, 1.30) 
.89* 
(.83, .96) 
Table 3: Hazard ratios for the Cox regressions. The asterisk (*) indicates significant results (p<.05). Values 
within the brackets indicate the 95% confidence interval. N: number of participants, MHT: Moray House Test, DS: 
Digit Symbol Substitution test, BF: brain fraction, OSCchildhood: occupational social class during childhood. 
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Highlights 
• Unexpectedly, klotho KL-VS heterozygotes survived shorter 
• KL-VS heterozygotes had larger right frontal lobe volumes 
• Cognitive decline was slower in KL-VS heterozygotes’ than non-carriers 
• Results indicate heterozygotes would have a cognitive advantage in very late life 
